Geranylgeranyl diphosphate synthase (GGDPS) is the enzyme in the isoprenoid biosynthesis pathway that catalyzes the synthesis of the 20-carbon isoprenoid GGPP, which serves as the isoprenoid donor for protein geranylgeranylation reactions. Rab proteins mediate vesicle trafficking within the cell and their activity is dependent on geranylgeranylation. Our prior work has demonstrated that agents that disrupt Rab geranylgeranylation disrupt monoclonal protein trafficking in myeloma cells, resulting in induction of the unfolded protein response pathway and apoptosis. VSW1198 is a potent GGDPS inhibitor with measurable cellular activity at concentrations as low as 30 nM. Due to its potent activity against myeloma cells in vitro, we were interested in evaluating the toxicology profile, pharmacokinetic (PK) profile, tissue distribution pattern and metabolic stability of VSW1198 in preparation for in vivo efficacy studies. Single dose testing via IV administration in CD-1 mice revealed a maximum tolerated dose of 0.5 mg/kg. Doses ≥1 mg/kg resulted in liver toxicity that peaked around 6-7 days post-injection. Disruption of protein geranylgeranylation following repeat dosing of VSW1198 was confirmed via immunoblot analysis of unmodified Rap1a in multiple organs. The PK studies revealed a half-life of 47.7 ± 7.4 h. VSW1198 was present in all tested tissues with the highest levels in the liver. In both human liver microsomes and mouse S9 studies VSW1198 showed complete stability, suggesting no phase I or phase II metabolism. In summary, these studies demonstrate systemic distribution, on-target disruption of protein geranylgeranylation, and metabolic stability of a potent GGDPS inhibitor VSW1198 and form the basis for future efficacy studies in mouse models of myeloma.
Introduction
Prenylation is a posttranslational modification that refers to the addition of a 15 -carbon (farnesyl) or a 20-carbon (geranylgeranyl) isoprenoid chain to a cysteine residue of a protein. The isoprenoid biosynthesis pathway (IBP) is responsible for the production of the isoprenoid donors (farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP)) used in the prenylation reactions. The largest family of prenylated proteins is the Ras small GTPase superfamily of proteins, which includes the Rab proteins. Rabs are pivotal regulators of intracellular membrane trafficking processes. Geranylgeranyl diphosphate synthase (GGDPS) generates the substrate GGPP, which is utilized by the enzymes geranylgeranyl transferases (I and II)
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10637-018-0571-3) contains supplementary material, which is available to authorized users.
to catalyze the addition of the 20-carbon isoprenoid moiety to carboxy terminal cysteine residues of target proteins, including Rap and Rab proteins. Geranylgeranylation of Rab proteins is critical to their normal function. For instance, mutant Rab5 and Rab27 proteins, which cannot be prenylated, are mistargeted to the endoplasmic reticulum and are nonfunctional in cellular assays [1] . Because Rab proteins regulate nearly all aspects of protein trafficking, including vesicle budding, motility, docking, and fusion, disruption of Rab activity via inhibition of its prenylation serves as a novel mechanism to disrupt protein handling in cells. GGDPS inhibitors deplete cells of GGPP, thus preventing the activity of geranylgeranyl transferases and interfering with Rab geranylgeranylation.
In multiple myeloma cells, GGDPS inhibitors hinder the secretion of monoclonal proteins, resulting in induction of ER stress, activation of the unfolded protein response (UPR) and apoptosis [2] . Because myeloma cells express near maximal levels of UPR-associated proteins to aid in the continuous production of monoclonal proteins, they are particularly sensitive to activation of the pro-apoptotic arm of the UPR [3] . We have therefore pursued the development of GGDPS inhibitors as a novel therapeutic strategy for myeloma. One of the most potent GGDPS inhibitors reported to date is VSW1198 (1, Fig. 1 ). This agent inhibits geranylgeranylation at concentrations as low as 30 nM in cell culture and is highly specific for GGDPS over other enzymes in the IBP pathway [4] . VSW1198 is a 3:1 mixture of homogeranyl and homoneryl isomers and subsequent preparation of individual isomers found the homoneryl to be the more potent isomer in cellular and enzymatic assays [5, 6] . However, the combination of the two isomers inhibited the enzyme more potently than either isomer alone, suggesting the isomers interact in a synergistic manner to inhibit GGDPS. Computer modeling predicts this synergy may in part be due to the preferential binding of each isomer to different sites within GGDPS [6] .
Given the potency and specificity of VSW1198 in vitro we have pursued the preclinical evaluation of this novel GGDPS inhibitor. To this end, we have performed dose escalation studies in CD-1 mice to determine the maximum tolerated single and multi-dose schedules for VSW1198. In addition, we conducted a pharmacokinetic (PK) study to evaluate the drug's half-life and other PK parameters, as well as its tissue distribution in vivo. These studies reveal that VSW1198 has systemic distribution and a relatively slow elimination rate. Furthermore, human liver microsome (HLM) and mouse S9 metabolism studies revealed the high metabolic stability of VSW1198. Collectively, these studies represent a pivotal step forward toward exploring the therapeutic efficacy of VSW1198 as an anti-myeloma drug.
Material and methods
Chemicals Professor David Wiemer at the University of Iowa kindly provided VSW1198 [4] and RAM3059 [7] .
Animals Female CD-1 mice (Charles River) between the ages of 6-8 weeks were housed in the University of Nebraska Medical Center (UNMC) animal facility at a temperature of 23-25°C, relative humidity of 50-70% and 12/12 h light/dark cycles. The UNMC IACUC (protocol number 16-132-11-FC) approved all animal studies.
Determination of maximum tolerated dose (MTD) Mice were injected by intravenous (IV) administration with VSW1198 or RAM3059 (dissolved in sterile PBS and filter sterilized). Standard dose escalation procedures were followed using the up-and-down method. To conserve animals, one mouse was injected at a time. The dosage was increased 1.8 times until mice showed signs of toxicity. After 7 days, if the first mouse survived the second mouse received a higher dose. If the first mouse died or was moribund, the second animal received a lower dose. The lowest dose that did not produce signs of toxicity was increased by 1.15 times until mice showed signs of toxicity. Dosing continued until three consecutive animals survived the upper bound.
Blood analysis Mouse blood samples were collected via cheek bleeds or post mortem from the heart in lithium-heparin coated tubes. Blood samples were analyzed using an Abaxis Vetscan2 instrument and the preventative care profile plus rotor. Complete blood count (CBC) measurements were obtained via whole blood using a scil Vet ABC Instrument. These instruments provided the normal ranges of laboratory values (Tables 1, 2, 3 and 4). Creatinine kinase and lactate Fig. 1 Chemical structures of GGDPS inhibitor (1, VSW1198) and the control compound (2, RAM3059) dehydrogenase levels were measured using colorimetric kits purchased from BioAssay systems (cat# D2Dh-100 and ECPK-100).
PK study Mice were divided into six groups with five mice per group and injected with 0.5 mg/kg VSW1198 (dissolved in sterile PBS and filter sterilized) via the tail vein. Blood was collected for 11 time points (5 min, 30 min, 1, 2, 4, 6, 8, 24, 48, 72, and 168 h) either by cheek bleed or post mortem from the heart and plasma separated. Tissues were collected at six time points (2, 8, 24, 48, 72 , and 168 h). VSW1198 was extracted from plasma and tissue samples via solid phase extraction followed by derivatization with diazomethane, and analyzed via LC-MS/MS as previously described [8] .
The PK parameters of VSW1198 in plasma were calculated using non-compartmental analysis with Phoenix WinNonlin 6.3 (Pharsight Corporation, Mountain view, CA). The maximum concentration (Cmax) and time to Cmax (Tmax) was obtained from the concentration time plot. The maximum concentration (C 0 ) at time zero was extrapolated. The area under the curve (AUC 0-∞ ) was estimated using the linear trapezoidal method from 0-t last and extrapolation from last time point to infinity based on the observed concentration at the last time point divided by the terminal elimination rate constant (k). The elimination half-life (t 1/2 ) was calculate using the formula of 0.693/k. For intravenous administration, clearance (CL) and the apparent volume of distribution of the elimination phase (Vd) were calculated as dose/AUC 0 -∞ and dose/k*AUC 0-∞ , respectively.
Histology Mouse organs were fixed in formalin for 24-96 h, stored in 70% ethanol, imbedded in paraffin, sectioned and stained (H&E) using standard methods at the UNMC Tissue Science Facility.
Western blot Tissues were homogenized in T-PER (Invitrogen) supplemented with proteinase inhibitors. Protein content was determined by the BCA method. Equal amounts of total protein were resolved by SDS-PAGE and then transferred to polyvinylidene difluoride membrane. Blots were incubated in primary and secondary antibodies and visualized using an ECL chemiluminescence detection kit and a Bio-Rad ChemiDoc MP imaging system. The following primary antibodies and antibody dilutions were used: Rap1a (Santa Cruz, cat# sc-1482, 1:250) and β-tubulin (Cell Signaling Technology, cat# 2146, 1:1000).
In vitro metabolism using human liver microsomes (HLM) for phase I metabolism For the microsomal stability experiment, human microsomal protein (1 mg/mL) (XenoTech LLC, Kansas) in a solution containing Tris buffer (50 mM, pH 7.4), magnesium chloride (20 mM) and NADPH (2 mM) Blood was collected at 7 and 14 days post injection (Mean ± SD, n = 5 per VSW1198 and n = 3 for RAM3059).
Abbreviations: blood urea nitrogen (BUN), creatinine (CRE), alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), total bilirubin (TBIL), glucose (GLU), total protein (TP), albumin (ALB), globulin (GLOB), lactate dehydrogenase (LDH), creatine kinase (Ck) and NR (not reported) (Sigma-Aldrich, MO) in a final volume of 1.0 mL was preincubated at 37°C for 10 min in a shaking water bath at 60 rpm. The reaction was started by adding 2 μM final concentration of VSW1198 (2 μL from 1 mM stock). Samples (100 μL) were collected at selected time intervals (0, 5, 10, 15, 20, 30, 45 and 60 min) and quenched with 100 μL of methanol. A control experiment was conducted without NADPH to reveal any chemical instability or non-cofactor dependent enzymatic degradation. A compound with known metabolism was used as a positive control. All samples were processed and derivatized according to our plasma sample processing method and supernatant (10 μL) was injected for LC-MS/ MS analysis [8] . The in vitro metabolic elimination rate constant was determined from the first order plot of natural logarithm of area ratio versus time.
In vitro metabolism using mouse S9 for phase I and phase II metabolism S9 fraction stability experiments were conducted utilizing a solution containing Tris buffer (50 mM,pH 7.4), mouse S9 fraction (1 mg/mL), magnesium chloride (20 mM), NADPH (2 mM), uridine diphosphate glucuronyltransferase (Sigma-Aldrich, MO) (2 mM), Adenosine 3'-Phosphate 5'-Phosphosulfate (PAPS, Sigma-Aldrich, MO) (0.1 mM), and saccharolactone (Sigma-Aldrich, MO) (5 mM). The final volume of 1.0 mL was pre-incubated at 37°C for 10 min in a water bath maintaining 60 rpm. The reaction was started by adding 2 μM final concentration of VSW1198 (2 μL from 1 mM stock). Samples (100 μL) were collected at different time intervals (0, 5, 15, 30, 45 60 and 120 min) and quenched with 100 μL of methanol. A control experiment was conducted without NADPH to reveal any chemical instability or non-cofactor dependent enzymatic degradation. All the samples were processed as our plasma sample processing method and supernatant (10 μL) was injected for LC-MS/MS analysis. A compound with known metabolism was used as a positive control. The in vitro metabolic elimination rate constant was determined from the first order plot of natural logarithm of area ratio versus time.
Results
Maximum tolerated dose of VSW1198 in CD-1 mice Single dose testing via IV administration in CD-1 mice revealed a MTD of 0.5 mg/kg. Doses ≥1 mg/kg resulted in liver toxicity that peaked around 6-7 days post-injection (Fig. 2a) .
Histopathological examination of the livers demonstrated centrilobular hepatocyte necrosis and apoptosis with invasion of inflammatory cells and panlobular hepatocyte swelling (Fig. 2a) . Analysis of blood samples from mice injected with 0.5 mg/kg VSW1198 showed elevated transaminase levels at 7 days without effects on bilirubin, alkaline phosphatase, lactic dehydrogenase, or albumin, consistent with the observed pattern of hepatic injury (Table 1) . By 14 days, transaminase levels returned to near normal. No hematological toxicity was observed as the majority of the CBC results were within normal range, with the exception of platelets, which were elevated in some animals and percentage of lymphocytes, which may be reflective of differences in mouse strains (Table 2 ). Histopathological examination of brains, kidney, and spleen revealed no abnormalities (Fig.  S1 ). Dosing at 0.5 mg/kg did not cause any significant weight loss over 14 days (Fig. S2) . These results indicate hepatic injury as being the primary barrier to dose escalation for VSW1198. A control compound, RAM3059 (2, Fig. 1 ), also was tested in vivo. This compound has a similar isoprenoid triazole bisphosphonate structure but is 380-fold less potent than VSW1198 as a GGDPS inhibitor [7] . Mice injected with RAM3059 (doses ranging from 0.28-1.6 mg/kg) were grossly and histologically normal with no signs of liver toxicity, suggesting liver injury is not a result of nonspecific toxicity from the triazole bisphosphonate structure (Fig. 2b) . Histopathological examination of the brains, kidneys, and spleen from the RAM3059-treated mice revealed no abnormalities (Fig. S1 ). In addition, no effects on hematological, renal, hepatic function, or weight were observed (Table 1, Table 2 and Fig. S3 ).
Maximum tolerated multi-dose of VSW1198 Mice were injected twice weekly with 0.1 mg/kg for a total of eight injections spread out over a period of five weeks (two weeks on, one week off, two weeks on). Histopathological examination revealed minor panlobular hepatocyte swelling (Fig. 3) , with no effects on kidney, spleen, and liver (Fig. S4) . Transaminase levels were within normal range at 21 days post-injection and mildly elevated at 35 days (Table 3) . CBC results were normal (Table 4 ). In addition, no significant weight loss was observed throughout the course of the experiment (Fig. S5) .
In vivo disruption of protein geranylgeranylation Rap1a is a representative geranylgeranylated protein and immunoblot analysis utilizing an antibody which is specific for unmodified Rap1a is commonly used to document disruption of protein geranylgeranylation [9] . As shown in Fig. 4 , immunoblot analysis of tissues obtained at the completion of the multidose treatment schedule reveals the accumulation of unmodified Rap1a in a variety of tissues. In comparison, little or no unmodified Rap1a is detected in the tissues of control animals that did not receive VSW1198 treatment.
Pharmacokinetic studies A PK study included 11 blood samples (5 min, 30 min, 1, 2, 4, 6, 8, 24, 48, 72, and 168 h) obtained post IV injection of VSW1198 at 0.5 mg/kg Blood was collected 21 and 35 days post initiation of injections (Mean ± SD, n = 3). Abbreviations: blood urea nitrogen (BUN), creatinine (CRE), alanine amino-transferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), total bilirubin (TBIL), glucose (GLU), total protein (TP), albumin (ALB), globulin (GLOB), LDH (lactate dehydrogenase), Ck (creatine kinase), and NR (not reported) ( Table 5 ). VSW1198 was extracted from plasma samples, derivatized by reaction with diazomethane, and analyzed via LC-MS/MS. The maximum plasma concentration (C 0 ) is 829.4 ng/mL ± 135.2, the area under curve (AUC0-∞) is 2748.5 ± 95.4 h*ng/mL, the plasma elimination half-life (t 1/2 ) is 47.7 ± 7.4 h, and the clearance rate is 0.182 ± 0.01 L/ h/kg (Table 5 ). Detectable concentrations of VSW1198 at 168 h (mean concentration of 3.2 ng/mL) indicate prolonged systemic exposure (Fig. 5) . The percentage extrapolation of AUC from the last measured time point to infinity was less than 5%. The initial rapid elimination in the plasma concentration suggest that the compound distributes into tissues from the blood. Furthermore, LC-MS/MS was able to detect and quantify individual E-and Z-isomers of VSW1198 (Fig. S6 , Table S1 and Table S2 ) in both plasma and tissue samples.
Tissue distribution Tissue samples (liver, kidney, spleen, lung, brain, and bone marrow) were collected at 2, 8, 24, 48, and 72 h from mice injected IV with 0.5 mg/kg VSW1198. VSW1198 was extracted from tissues and quantified via LC-MS/MS as previously described [8] . VSW1198 was detected in all studied tissues including bone marrow, brain, liver, spleen, and kidney ( Fig. 6 and Table S2 ). In addition, our data show that the tissue to plasma concentration ratio (Kp) is ≥1 in all tissues, except brain and bone marrow. The concentration of VSW1198 in tissues was found to be highest in the liver (1440.0 ± 430.5 ng/g at two hours). Importantly, the VSW1198 concentration in the bone marrow at 24 h was 18.2 ± 3.0 ng/mL (equivalent to 37 nM), which is greater than the lowest in vitro concentration required to disrupt protein geranylgeranylation [4] . These data demonstrate VSW1198 has systemic distribution in vivo with limited ability to cross the blood-brain barrier.
In vitro metabolism of VSW1198 The metabolic stability of VSW1198 was assessed using HLM and mouse S9 fractions to evaluate phase I and phase II metabolism. VSW1198 was not metabolized (≤15%) in HLM or mouse S9 fraction in the presence and absence of the metabolizing enzymes, indicating that it does not undergo cytochrome P-450 (CYP)-mediated or Phase II metabolism (Fig. 7) . In comparison, a positive control with known metabolism showed rapid metabolic degradation (Fig. 7) . No additional peaks including peaks specific to predicted phase I and phase II metabolites were detected by LC/ MS/MS after incubation of VSW1198 in HLM or S9 fractions (data not shown). Based on these results and the tissue distribution studies, VSW1198 appears to be metabolically stable. 
Discussion
These studies represent the first in vivo assessment of one of the most potent GGDPS inhibitors reported to date. Notably, these studies demonstrate that VSW1198 is characterized by having a long half-life, systemic distribution, metabolic stability, and can effectively disrupt protein geranylgeranylation without causing unacceptable toxicity. From a myeloma perspective, the drug could be detected in the bone marrow, supporting the need for future studies evaluating in vivo anti-myeloma activity. Intriguingly, the Z-isomer had enhanced uptake in the bone marrow compared to the E-isomer. The mechanisms by which olefin stereochemistry dictates organ-specific uptake and clearance of isoprenoid compounds is unknown and warrants further investigation. To date, there have been only two previously published reports involving the in vivo assessment of a GGDPS inhibitor. The inhibitor used in those studies, GGOHBP [10] , is approximately 18-fold less potent than VSW1198 (IC 50 of 800 nM) [11] . In the first report, Reilly et al., demonstrated that daily subcutaneous injection of GGOHBP (either 1.25 or 1.5 mg/kg) for 31 days in male SCID mice did not significantly alter mouse weight [12] . They then utilized a metastatic prostate cancer model in which the SCID mice underwent intracardiac injection of luciferase-expressing 22Rv1 cells. Treatment of the mice with GGOHBP did not alter metastasis formation, but did decrease adrenal gland tumor weight. The higher dose of GGOHBP in tumor-bearing mice did cause significant weight loss, but no other toxicological descriptions were provided. The authors were unable to demonstrate GGOHBPinduced disruption of protein geranylgeranylation in vivo in either normal tissues or tumors, with the exception of the adrenal tumors which did show accumulation of unmodified Rap1a. In the second report, Reilly et al., treated SCID mice with GGOHBP (1.25 mg/kg SC) for four days prior to tail vein injection of luciferase-expressing PC3 cells [11] . In this model, treatment with GGOHBP slowed tumor development and improved survival. Analysis of tissues demonstrated that unmodified Rap1a could be detected in a variety of metastatic tumors but not in normal tissues. That we were able to detect unmodified Rap1a in a variety of normal tissues in treated mice is likely a consequence of the enhanced potency of VSW1198 as a GGDPS inhibitor as well as its superior biodistribution.
Further studies need to be performed to better understand the dose-limiting hepatic toxicity observed with VSW1198. That the structurally-similar compound RAM3059 did not induce liver Fig. 4 Detection of unmodified Rap1a in mouse tissue following VSW1198 treatment. Liver, kidney and spleen were collected from mice injected with multiple doses of 0.1 mg/kg VSW1198 (two injections per week for five weeks with no injections during week three). Immunoblot analysis of tissue homogenate was performed using antibodies to detect unmodified Rap1a and β-tubulin (loading control). Lysates generated from U266 human myeloma cells treated with lovastatin were used as a positive control for unmodified Rap1a protein damage suggests that the toxicity observed with VSW1198 is not related to nonspecific toxicity from the triazole moiety, but instead is related to GGDPS inhibition. However, whether these effects are due to disruption of GGTase I substrate geranylgeranylation, GGTase II substrate geranylgeranylation, and/or perturbation of intracellular isoprenoid levels remains to be determined. The studies utilizing GGOHBP did not include any descriptions of toxicology effects aside from animal weight. There is one report which assessed the in vivo activity of a GGTase I inhibitor (P661A6) [13] . Female SCID mice were treated with daily intraperitoneal dosing for 10 days. The authors reported only mild liver transaminase elevation at ≥2.32 mg/kg dosing without histopathological alteration and showed that inhibition of tumor growth (pancreatic cancer xenograft model) could be achieved. While our studies have focused on the development of VSW1198 as an anti-myeloma agent, there is in vitro and in vivo evidence that GGDPS inhibitors have activity against other cancer types [11, 12, [14] [15] [16] [17] and it will therefore be important to assess the in vivo activity of VSW1198 in other tumor models. Finally, there is also evidence that GGDPS inhibitors may have activity in non-malignant conditions such as fibrotic lung disease. [18] Collectively, these studies lay the foundation for future efficacy testing of VSW1198 and development of VSW1198 as a first-in-class GGDPS inhibitor.
